Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users.

Knowlton A, Arnsten J, Eldred L, Wilkinson J, Gourevitch M, Shade S, Dowling K, Purcell D; INSPIRE Team.

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):486-92.

PMID:
16652058
2.

Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: the role of informal caregiving and household factors.

Knowlton AR, Arnsten JH, Gourevitch MN, Eldred L, Wilkinson JD, Rose CD, Buchanan A, Purcell DW; INSPIRE Study Team.

J Acquir Immune Defic Syndr. 2007 Nov 1;46 Suppl 2:S110-9. doi: 10.1097/QAI.0b013e31815767f8.

PMID:
18089980
3.

Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.

Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, Tyndall M, Wood E.

Antivir Ther. 2004 Jun;9(3):407-14.

PMID:
15259903
4.

Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.

Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS.

J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):522-6.

PMID:
12679704
5.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

PMID:
15319852
6.

Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors.

Knowlton AR, Arnsten JH, Eldred LJ, Wilkinson JD, Shade SB, Bohnert AS, Yang C, Wissow LS, Purcell DW.

AIDS Patient Care STDS. 2010 Jul;24(7):421-8. doi: 10.1089/apc.2009.0240.

7.

Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.

Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, Gallant JE.

AIDS. 2001 Sep 7;15(13):1707-15.

PMID:
11546947
8.

A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users.

Macalino GE, Hogan JW, Mitty JA, Bazerman LB, Delong AK, Loewenthal H, Caliendo AM, Flanigan TP.

AIDS. 2007 Jul 11;21(11):1473-7.

PMID:
17589194
9.

Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.

Lucas GM, Cheever LW, Chaisson RE, Moore RD.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):251-9.

PMID:
11464144
10.

Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users.

Clarke S, Delamere S, McCullough L, Hopkins S, Bergin C, Mulcahy F.

HIV Med. 2003 Jan;4(1):33-7.

11.

Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.

Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS.

Drug Alcohol Depend. 2006 Sep 15;84(2):188-94. Epub 2006 Mar 20.

PMID:
16542797
12.

Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups.

Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD.

Clin Infect Dis. 2006 Jun 1;42(11):1628-35. Epub 2006 Apr 28.

PMID:
16652321
13.
14.

Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.

Tun W, Gange SJ, Vlahov D, Strathdee SA, Celentano DD.

Clin Infect Dis. 2004 Apr 15;38(8):1167-74. Epub 2004 Apr 5.

PMID:
15095224
15.

Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras.

Galai N, Vlahov D, Bareta JC, Wang C, Cohn S, Sterling TR.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):74-81.

PMID:
15608529
16.

Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.

Tyndall MW, McNally M, Lai C, Zhang R, Wood E, Kerr T, Montaner JG.

Int J Drug Policy. 2007 Aug;18(4):281-7. Epub 2006 Dec 27.

PMID:
17689376
17.

Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users.

Carrieri MP, Chesney MA, Spire B, Loundou A, Sobel A, Lepeu G, Moatti JP; MANIF Study Group.

Int J Behav Med. 2003;10(1):1-14.

PMID:
12581944
18.

Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

Antivir Ther. 2004 Apr;9(2):229-35.

PMID:
15134185
19.

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, Hellinger J, Keiser P, Rubin HR, Crane L, Hellinger FJ, Mathews WC; HIV Research Network.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103.

PMID:
15608532
20.

Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour.

Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M.

Addiction. 2006 Mar;101(3):433-40.

PMID:
16499516

Supplemental Content

Support Center